Therapeutic Response

ER positive and PR positive status confers therapeutic sensitivity to Anastrozole in patients with Invasive Breast Carcinoma.

Statements

Source and description
Arimidex (anastrozole) [summary of product characteristics]. HPRA. The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized anastrozole for the treatment of patients who are postmenopausal women with hormone receptor-positive advanced breast cancer.
Arimidex (anastrozole) [summary of product characteristics]. HPRA. The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized anastrozole for the adjuvant treatment of patients who are postmenopausal women with hormone receptor-positive early invasive breast cancer.
Arimidex (anastrozole) [summary of product characteristics]. HPRA. The Republic of Ireland's Health Products Regulatory Authority (HPRA) has authorized anastrozole for the adjuvant treatment of patients who are postmenopausal women with hormone receptor-positive early invasive breast cancer who have received 2 to 3 years of adjuvant tamoxifen.
Anastrozole Monotherapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved anastrozole as a treatment option for extended adjuvant treatment of patients who are postmenopausal women with hormone-dependent-invasive breast cancer who have received 2 to 3 years of adjuvant tamoxifen.